EcoDrugPlus

Mu-Type Opioid Receptor-Like

Ensembl ID : ENSNBRG00000014216
Gene Symbol: LOC102791192
3 Cross references
214 Possible Orthologues:

Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1-Like

Ensembl ID : ENSNBRG00000022858
Gene Symbol: LOC102781556
2 Cross references
195 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSNBRG00000010300
Gene Symbol: LOC102794742
3 Cross references
195 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSNBRG00000001506
Gene Symbol: LOC102788441
3 Cross references
189 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSNBRG00000006798
Gene Symbol: LOC102777573
3 Cross references
196 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSNBRG00000007991
Gene Symbol: LOC102781390
3 Cross references
197 Possible Orthologues:

Neurogenic Locus Notch Protein Homolog

Ensembl ID : ENSNBRG00000013144
Gene Symbol: LOC102783060
3 Cross references
201 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSNBRG00000013440
Gene Symbol: LOC102788798
3 Cross references
218 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSNBRG00000004869
Gene Symbol: LOC102780443
3 Cross references
199 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-4-Like

Ensembl ID : ENSNBRG00000021495
Gene Symbol: LOC102795726
3 Cross references
193 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSNBRG00000020709
Gene Symbol: LOC102789399
3 Cross references
205 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSNBRG00000007033
Gene Symbol: NPY2R
3 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).